<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057352</url>
  </required_header>
  <id_info>
    <org_study_id>CDM10001448</org_study_id>
    <nct_id>NCT04057352</nct_id>
  </id_info>
  <brief_title>Citadel Feasibility Study</brief_title>
  <official_title>The Citadel Embolization Device Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this feasibility study is to gather preliminary safety and effectiveness data
      on Citadel Embolization Device in the treatment of wide-neck intracranial aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this feasibility study, use of the Citadel Embolization Device will be limited to a
      population of patients with unruptured wide-neck aneurysms who meet all study eligibility
      criteria. The Citadel Embolization Device is intended to endovascularly obstruct or occlude
      blood flow in intracranial aneurysms.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">July 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Outcome</measure>
    <time_frame>Time of Index Procedure</time_frame>
    <description>Primary Procedural Outcome Measure of the study is successful Citadel Embolization Device deployment to the target aneurysm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>12 month post-procedure</time_frame>
    <description>A safety endpoint is stroke-related neurologic death, or major ipsilateral or disabling stroke in the territory supplied by the treated artery, occurring within 12 months post-procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unruptured Wide-neck Aneurysms</condition>
  <arm_group>
    <arm_group_label>Citadel Embolization Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Citadel Embolization Device</intervention_name>
    <description>The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.</description>
    <arm_group_label>Citadel Embolization Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Has a single, unruptured target intracranial aneurysm that is suitable for endovascular
        treatment.

        Exclusion Criteria:

        1. Target aneurysm has been previously treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

